Menu

Infographic: A Painful Pathway

Since the mid-2000s, the voltage-gated sodium channel NaV1.7 has emerged as a promising target for a new class of analgesics.

Dec 31, 2017
Catherine Offord

© THOM GRAVES

NaV1.7 controls the passage of sodium ions into sensory neurons. Hyperactivity in NaV1.7 is associated with increased firing in pain-sensing neurons—and thus agony even in the absence of painful stimuli—while deletion of the channel appears to cause pain insensitivity.

© THOM GRAVESLike other voltage-gated sodium channels, NaV1.7 consists of four voltage-sensing domains (I to IV) surrounding a central pore through which sodium ions pass into the neuron. As a sensory neuron fires (from left to right), voltage-gated sodium channels cycle through three states: from closed to open, and finally inactivated.

INACTIVATED
For a short period following opening, the voltage-sensing domains remain open, but the pore is blocked by a positively charged particle in a ball-and-chain mechanism.

OPEN
Voltage-sensing domains open during an action potential to allow sodium ions to flow into the neuron.

CLOSED
Voltage-sensing domains pinch shut the pore when the neuron is at rest.

Precision Targeting

Many companies are working to develop molecules that inhibit the NaV1.7 channel. But while the basics of the protein complex’s function are well established, researchers are still learning how best to target NaV1.7 in order to achieve analgesia. Early attempts to inhibit the channel used small molecules to block the pore region, but because this pore is well-conserved among the NaV family, these drugs generally showed low selectivity for NaV1.7. Recent efforts have targeted the less-conserved voltage-sensing domains of NaV1.7 to lock the channel in a closed or inactivated state. Hitting the right part of the protein is not the only challenge—even with the development of apparently highly potent NaV1.7 blockers, researchers are now questioning just where along a sensory neuron a drug needs to act in order to be maximally analgesic.

© THOM GRAVES

A. Small molecules that target NaV1.7’s voltage-sensing domains show high specificity for the receptor, and have shown promise in early stage trials.

B. Toxin-derived peptides also show high specificity for NaV1.7’s voltage-sensing domains, and promising preclinical results have piqued the interest of a handful of companies.

C. Drugs that target the channel’s pore are relatively nonselective, and few are currently being pursued as analgesics.

 

 

 

 

© THOM GRAVEThe failure of many supposed NaV1.7 blockers to effectively blunt pain has some researchers questioning the assumption that inhibiting NaV1.7 in the periphery is sufficient. Because sensory neurons often have axons that terminate inside the central nervous system, drugs targeting NaV1.7 may need to cross the blood-brain barrier to boost their painkilling effect.

Read the full story.

 

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!